Sunitinib Alone or after Nephrectomy in Renal Cancer

In the CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiog éniques) trial, Méjean et al. (Aug. 2 issue)1 determine the noninferiority of sunitinib alone, as compared with nephrectomy followed by sunitinib, on the basis of the observation that the 95% confidence interval for the hazard ratio of death did not exceed 1.20 (the noninferiority margin for t he trial).11/09/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news